IP Library › Granted Patent US 9,145,396
Granted Patent B2
US 9,145,396 · App. 14/074,147 · Granted Sep 29, 2015

Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine

Inventors: Srinivasa Rao Akireddy (Winston-Salem, NC); Balwinder Singh Bhatti (Winston-Salem, NC); Timothy J. Cuthbertson (Winston-Salem, NC); Gary Maurice Dull (Lewisville, NC); Craig Harrison Miller (Winston-Salem, NC); Joseph Pike Mitchener (Winston-Salem, NC); Julio A. Munoz (Walnut Cove, NC); Pieter Albert Otten (King, NC)
Assignee: Targacept, Inc.
C07D403/06A61K31/4025C07C59/255C07C59/265
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,145,396
App. No.
14/074,147
Granted
Sep 29, 2015
Kind
B2
Abstract

The present invention relates to the stereospecific synthesis of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, its salt forms, and novel polymorphic forms of these salts.

Claims (3)

1. A mono-citrate salt of a compound (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine substantially free of (S)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine.

2. A pharmaceutical composition comprising (R)-5-(((E)-2-pyrrolidin-3-ylvinyl)pyrimidine mono-citrate substantially free of (S)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine mono-citrate and one or more pharmaceutically acceptable carriers, diluents, excipients, or adjuvants.

3. A method of treating constipation in a patient in need thereof comprising administration of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine mono-citrate substantially free of (S)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine mono-citrate.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Feb 3, 2023
From: ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP
To: OYSTER POINT PHARMA INC.
Reel/Frame 062582/0873 →
CORRECTIVE ASSIGNMENT TO CORRECT THE THE CONVEYING PARTY EXECUTION DATE PREVIOUSLY RECORDED AT REEL: 041044 FRAME: 0211. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Oct 26, 2021
From: TARGACEPT, INC.
To: CATALYST BIOSCIENCES, INC.
Reel/Frame 057923/0518 →
PATENT SECURITY AGREEMENT Recorded Aug 5, 2021
From: OYSTER POINT PHARMA, INC.
To: ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP
Reel/Frame 057104/0189 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2017
From: CATALYST BIOSCIENCES, INC.
To: OYSTER POINT PHARMA, INC.
Reel/Frame 041043/0769 →
CHANGE OF NAME Recorded Jan 13, 2017
From: TARGACEPT, INC.
To: CATALYST BIOSCIENCES, INC.
Reel/Frame 041044/0211 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2017
From: AKIREDDY, SRINIVASA RAO; BHATTI, BALWINDER SINGH; CUTHBERTSON, TIMOTHY J.; DULL, GARY MAURICE; MILLER, CRAIG HARRISON; MITCHENER, JOSEPH PIKE, JR; MUNOZ, JULIO A.; OTTEN, PIETER ALBERT
To: TARGACEPT, INC.
Reel/Frame 040904/0482 →
Continuity (3)
Continuation 13129898
Provisional Application 61118796 · Dec 1, 2008
Related Publication 20140066460A1 · Mar 6, 2014